Novartis wins European recs for a pair of new Cosentyx uses

With a raft of next-gen psoriasis competitors coming up Big Pharma's pipelines, Novartis ($NVS) is looking to distinguish Cosentyx by adding a pair of new uses. And it got one step closer on Friday, winning approval recommendations from European regulators for use of the med in both psoriatic arthritis and ankylosing spondylitis. Release